Abstract
Study design:
Review study.
Objectives:
The identification of prognostic biomarkers of spinal cord injury (SCI) will help to assign SCI patients to the correct treatment and rehabilitation regimes. Further, the detection of biomarkers that predict permanent neurological outcome would aid in appropriate recruitment of patients into clinical trials. The objective of this review is to evaluate the current state-of-play in this developing field.
Setting:
Studies from multiple countries were included.
Methods:
We have completed a comprehensive review of studies that have investigated prognostic biomarkers in either the blood or cerebrospinal fluid (CSF) of animals and humans following SCI.
Results:
Targeted and unbiased approaches have identified several prognostic biomarkers in CSF and blood. These proteins associate with cellular damage following SCI and include components from neurons, oligodendrocytes and reactive astrocytes, that is, neurofilament proteins, glial fibrillary acidic protein, Tau and S100 calcium-binding protein β. Unbiased approaches have also identified microRNAs that are specific to SCI, as well as other cell damage-associated proteins.
Conclusions:
The discovery and validation of stable, specific, sensitive and reproducible biomarkers of SCI is a rapidly expanding field of research. So far, few studies have utilised unbiased approaches aimed at the discovery of biomarkers within the CSF or blood in this field; however, some targeted approaches have been successfully used. Several studies using various animal models and some with small human patient cohorts have begun to pinpoint biomarkers in the CSF and blood with putative prognostic value. An increased sample size will be required to validate these biomarkers in the heterogeneous clinical setting.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Medicine Consortium for Spinal Cord. Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med 2008; 31: 404–479.
Masri E . Management of traumatic spinal cord injuries: current standard of care revisited. Adv Clin Neurosci Rehabil 2010; 10: 37–40.
Tuszynski MH, Steeves JD, Fawcett JW, Lammertse D, Kalichman M, Rask C et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord 2007; 45: 222–231.
Fehlings MG, Vaccaro A, Wilson JR, Singh A, Cadotte DW, Harrop JS et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the surgical timing in acute spinal cord injury study (STASCIS). PLoS ONE 2012; 7: e32037.
Fawcett JW, Curt A, Steeves JD, Coleman WP, Tusynski MH, Lammertse D et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007; 45: 190–205.
El Masri WS, Kumar N . Traumatic spinal cord injuries. Lancet 2011; 377: 972–974.
Bunge RP, Puckett WR, Becerra JL, Marcillo A, Quencer RM . Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. Adv Neurol 1993; 59: 75–89.
Bunge RP, Puckett WR, Hiester ED . Observations on the pathology of several types of human spinal cord injury, with emphasis on the astrocyte response to penetrating injuries. Adv Neurol 1997; 72: 305–315.
Pouw MH, Kwon BK, Verbeek MM, Vos PE, van KA, Fisher CG et al. Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects. Spinal Cord 2014; 52: 428–433.
Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence of tau. Neurosci Lett 1995; 186: 181–183.
Wolf H, Krall C, Pajenda G, Leitgeb J, Bukaty AJ, Hajdu S et al. Alterations of the biomarker S-100B and NSE in patients with acute vertebral spine fractures. Spine J 2014; 14: 2918–2922.
Zetterberg H, Smith DH, Blennow K . Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol 2013; 9: 201–210.
Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T . IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: Relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol 1999; 101: 211–221.
Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L . Acute inflammatory response in spinal cord following impact injury. Exp Neurol 1998; 151: 77–88.
Trivedi A, Olivas AD, Noble-Haeusslein LJ . Inflammation and spinal cord injury: Infiltrating leukocytes as determinants of injury and repair processes. Clin Neurosci Res 2006; 6: 283–292.
Biglari B, Swing T, Child C, Buchler A, Westhausser F, Bruckner T et al. A pilot study on temporal changes in IL-1β and TNF-α serum levels after spinal cord injury: the serum level of TNF-α in acute SCI patients as a possible marker for neurological remission. Spinal Cord 2015; 53: 510–514.
Janssen O, Qian J, Linkermann A, Kabelitz D . CD95 ligand—death factor and costimulatory molecule? Cell Death Differ 2003; 10: 1215–1225.
Silver J, Miller JH . Regeneration beyond the glial scar. Nat Rev Neurosci 2004; 5: 146–156.
Cole GJ, McCabe CF . Identification of a developmentally regulated keratan sulfate proteoglycan that inhibits cell adhesion and neurite outgrowth. Neuron 1991; 7: 1007–1018.
Katoh-Semba R, Matsuda M, Kato K, Oohira A . Chondroitin sulphate proteoglycans in the rat brain: candidates for axon barriers of sensory neurons and the possible modification by laminin of their actions. Eur J Neurosci 1995; 7: 613–621.
Kastin AJ, Pan W . Targeting neurite growth inhibitors to induce CNS regeneration. Curr Pharm Des 2005; 11: 1247–1253.
McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE . Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 1994; 13: 805–811.
Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA et al. Nogo-A is a myelinassociated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000; 403: 434–439.
Fournier AE, GrandPre T, Strittmatter SM . Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 2001; 409: 341–346.
Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002; 417: 941–944.
Oertle T, van der Haar ME, Bandtlow CE, Robeva A, Burfeind P, Buss A et al. Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J Neurosci 2003; 23: 5393–5406.
Wright KT, Masri WEI, Osman A, Roberts S, Chamberlain G, Ashton BA et al. Bone marrow stromal cells stimulate neurite outgrowth over neural proteoglycans (CSPG), myelin associated glycoprotein and Nogo-A. Biochem Biophys Res Commun 2007; 354: 559–566.
Wright KT, Uchida K, Bara JJ, Roberts S, Masri WEl, Johnson WEB . Spinal motor neurite outgrowth over glial scar inhibitors is enhanced by coculture with bone marrow stromal cells. Spine J 2014; 14: 1722–1733.
Bradbury EJ, Moon LDF, Popat RJ, King VR, Bennett GS, Patel PN et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002; 416: 636–640.
Freund P, Wannier T, Schmidlin E, Bloch J, Mir A, Schwab ME et al. Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey. J Comp Neurol 2007; 502: 644–659.
Zhao RR, Andrews MR, Wang D, Warren P, Gullo M, Schnell L et al. Combination treatment with anti-Nogo-A and chondroitinase ABC is more effective than single treatments at enhancing functional recovery after spinal cord injury. Eur J Neurosci 2013; 38: 2946–2961.
Hayes KC, Hull TCL, Delaney GA, Potter PJ, Sequeira KAJ, Campbell K et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma 2002; 19: 753–761.
Marquardt G, Setzer M, Theisen A, Tews D-S, Seifert V . Experimental subacute spinal cord compression: correlation of serial S100B and NSE serum measurements, histopathological changes, and outcome. Neurol Res 2011; 33: 421–426.
Shaw G, Yang C, Ellis R, Anderson K, Mickle JP, Scheff S et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 2005; 336: 1268–1277.
Ungureanu D, Dimitriu C, Iencean AS, Tascu A . Determination of the phosphorylated neurofilament subunit NF-H (pNF-H) in cerebro-spinal fluid as biomarker in acute traumatic spinal cord injuries. Rev Rom Med Lab 2014; 22: 377–387.
Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW . Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics 2016; 13: 1.
Light M, Minor KH, DeWitt P, Jasper KH, Davies SJ . Multiplex array proteomics detects increased MMP-8 in CSF after spinal cord injury. J Neuroinflammation 2012; 9: 122.
Hachisuka S, Kamei N, Ujigo S, Miyaki S, Yasunaga Y, Ochi M . Circulating microRNAs as biomarkers for evaluating the severity of acute spinal cord injury. Spinal Cord 2014; 52: 596–600.
Sengupta MB, Basu M, Iswarari S, Mukhopadhyay KK, Sardar KP, Acharyya B et al. CSF proteomics of secondary phase spinal cord injury in human subjects: perturbed molecular pathways post injury. PLoS ONE 2014; 9: e110885.
Lubieniecka JM, Streijger F, Lee JHT, Stoynov N, Liu J, Mottus R et al. Biomarkers for severity of spinal cord injury in the cerebrospinal fluid of rats. PLoS ONE 2011; 6: e19247.
Moghieb A, Bramlett H, Das J, Yang Z, Selig T, Yost R et al. Differential neuroproteomic and systems biology analysis of spinal cord injury. Mol Cell Proteomics 2016; 15: 2379–2395.
Xu D, Omura T, Masaki N, Arima H, Banno T, Okamoto A et al. Increased arachidonic acid-containing phosphatidylcholine is associated with reactive microglia and astrocytes in the spinal cord after peripheral nerve injury. Sci Rep 2016; 6: 26427.
Dunn WB . Mass spectrometry in systems biology an introduction. Methods Enzymol 2011; 500: 15–35.
Peng J, Zeng J, Cai B, Yang H, Cohen M, Chen W et al. Establishment of quantitative severity evaluation model for spinal cord injury by metabolomic fingerprinting. PLoS ONE 2014; 9: 93736.
Vijayaprakash KM, Sridharan N . An experimental spinal cord injury rat model using customized impact device: a cost-effective approach. J Pharmacol Pharmacother 2013; 4: 211–213.
Koozekanani SH, Vise WM, Hashemi RM, McGhee RB . Possible mechanisms for observed pathophysiological variability in experimental spinal cord injury by the method of Allen. J Neurosurg 1976; 44: 429–434.
Zhang N, Fang M, Chen H, Gou F, Ding M . Evaluation of spinal cord injury animal models. Neural Regen Res 2014; 9: 2008–2012.
Gruner JA, Yee AK, Blight AR . Histological and functional evaluation of experimental spinal cord injury: evidence of a stepwise response to graded compression. Brain Res 1996; 729: 90–101.
Onifer SM, Rabchevsky AG, Scheff SW . Rat models of traumatic spinal cord injury to assess motor recovery. ILAR J 2007; 48: 385–395.
Xu XM, Chen A, Guénard V, Kleitman N, Bunge MB . Bridging Schwann cell transplants promote axonal regeneration from both the rostral and caudal stumps of transected adult rat spinal cord. J Neurocytol 1997; 26: 1–16.
Fouad K, Schnell L, Bunge MB, Schwab ME, Liebscher T, Pearse DD . Combining schwann cell bridges and olfactory-ensheathing glia grafts with chondroitinase promotes locomotor recovery after complete transection of the spinal cord. J Neurosci 2005; 25: 1169–1178.
Miller CCJ, Ackerley S, Brownlees J, Grierson AJ, Jacobsen NJO, Thornhill P . Axonal transport of neurofilaments in normal and disease states. Cell Mol Life Sci 2002; 59: 323–330.
Al-Chalabi A, Miller CCJ . Neurofilaments and neurological disease. BioEssays 2003; 25: 346–355.
Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 2013; 8: 9.
Kuhle J, Malmestrom C, Axelsson M, Plattner K, Yaldizli O, Derfuss T et al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013; 128: e33–e36.
Trentini A, Comabella M, Tinotore M, Koel-Simmelink MJ, Killestein J, Roos B et al. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol 2014; 261: 2338–2343.
Weydt P, Oeckl P, Huss A, Müller K, Volk AE, Kuhle J et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016; 79: 152–158.
Cai JY, Lu C, Chen MH, Ba HJ, Chen XD, Lin JH et al. Predictive value of phosphorylated axonal neurofilament subunit H for clinical outcome in patients with acute intracerebral hemorrhage. Clin Chim Acta 2013; 424: 182–186.
Millecamps S, Gowing G, Corti O, Mallet J, Julien JP . Conditional NF-L transgene expression in mice for in vivo analysis of turnover and transport rate of neurofilaments. J Neurosci 2007; 27: 4947–4956.
Yuan A, Sasaki T, Rao MV, Kumar A, Kanumuri V, Dunlop DS et al. Neurofilaments form a highly stable stationary cytoskeleton after reaching a critical level in axons. J Neurosci 2009; 29: 11316–11329.
Ueno T, Ohori Y, Ito J, Hoshikawa S, Yamamoto S, Nakamura K et al. Hyperphosphorylated neurofilament NF-H as a biomarker of the efficacy of minocycline therapy for spinal cord injury. Spinal Cord 2011; 49: 333–336.
Nishida H, Nakayama M, Tanaka H, Kamishina H, Izawa T, Hatoya S et al. Evaluation of serum phosphorylated neurofilament subunit NF-H as a prognostic biomarker in dogs with thoracolumbar intervertebral disc herniation. Vet Surg 2014; 43: 289–293.
Ahadi R, Khodagholi F, Daneshi A, Vafaei A, Mafi AA, Jorjani M . Diagnostic value of serum levels of GFAP, pNF-H, and NSE compared with clinical findings in severity assessment of human traumatic spinal cord injury. Spine 2015; 40: E823–E830.
Guéz M, Hildingsson C, Rosengren L, Karlsson K, Toolanen G . Nervous tissue damage markers in cerebrospinal fluid after cervical spine injuries and whiplash trauma. J Neurotrauma 2003; 20: 853–858.
Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 2015; 86: 273–279.
Brandt R, Lee G . The balance between tau protein’s microtubule growth and nucleation activities: implications for the formation of axonal microtubules. J Neurochem 1993; 61: 997–1005.
Wang JZ, Liu F . Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008; 85: 148–175.
Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW . A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 1975; 72: 1858–1862.
Drubin DG, Kirschner MW . Tau protein function in living cells. J Cell Biol 1986; 103: 2739–2746.
Blennow KB . CSF biomarkers for mild cognitive impairment. J Intern Med 2004; 256: 224–234.
Roerig A, Carlson R, Tipold A, Stein VM . Cerebrospinal fluid tau protein as a biomarker for severity of spinal cord injury in dogs with intervertebral disc herniation. Vet J 2013; 197: 253–258.
Kwon BK, Stammers AMT, Belanger LM, Bernardo A, Chan D, Bishop CM et al. Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma 2010; 27: 669–682.
Kwon BK, Streijger F, Fallah N, Noonan VK, Belanger LM, Ritchie L et al. Cerebrospinal fluid biomarkers to stratify injury severity and predict outcome in human traumatic spinal cord injury. J Neurotrauma 2016; 33: 1–14.
Rech TH, Vieira SR, Nagel F, Brauner JS, Scalco R . Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study. Crit Care 2006; 10: R133.
Tiainen M, Roine RO, Pettilä V, Takkunen O . Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. Stroke 2003; 34: 2881–2886.
Cao F, Yang X, Liu W, Hu W, Li G, Zheng X et al. Elevation of neuron-specific enolase and S-100beta protein level in experimental acute spinal cord injury. J Clin Neurosci 2008; 15: 541–544.
Loy DN, Sroufe AE, Pelt JL, Burke DA, Cao QL, Talbott JF et al. Serum biomarkers for experimental acute spinal cord injury: rapid elevation of neuron-specific enolase and S-100beta. Neurosurgery 2005; 56: 391–397.
Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR et al. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci 2003; 21: 109–121.
Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F et al. S100B’s double life: Intracellular regulator and extracellular signal. Biochim Biophys Acta 2009; 1793: 1008–1022.
Ma J, Novikov LN, Karlsson K, Kellerth JO, Wiberg M . Plexus avulsion and spinal cord injury increase the serum concentration of S-100 protein: an experimental study in rats. Scand J Plast Reconstr Surg Hand Surg 2001; 35: 355–359.
Diaz-Arrastia R, Wang KKW, Papa L, Sorani MD, Yue JK, Puccio AM et al. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma 2014; 31: 19–25.
Yokobori S, Zhang Z, Moghieb A, Mondello S, Gajavelli S, Dietrich WD et al. Acute diagnostic biomarkers for spinal cord injury: review of the literature and preliminary research report. World Neurosurg 2015; 83: 867–878.
Davies AL, Hayes KC, Dekaban GA . Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch Phys Med Rehabil 2007; 88: 1384–1393.
Hasturk A, Atalay B, Calisaneller T, Ozdemir O, Oruckaptan H, Altinors N . Analysis of serum pro-inflammatory cytokine levels after rat spinal cord ischemia/reperfusion injury and correlation with tissue damage. Turk Neurosurg 2009; 19: 353–359.
Wang CX, Olschowka JA, Wrathall JR . Increase of interleukin-1beta mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res 1997; 759: 190–196.
Zhang N, Yin Y, Xu SJ, Wu YP, Chen WS . Inflammation & apoptosis in spinal cord injury. Indian J Med Res 2012; 135: 287–296.
Shudo K, Kinoshita K, Imamura R, Fan H, Hasumoto K, Tanaka M et al. The membrane-bound but not soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 2001; 31: 2504–2511.
Biglari B, Buchler A, Swing T, Biehl E, Roth HJ, Bruckner T et al. Increase in soluble CD95L during subacute phases after human spinal cord injury: a potential therapeutic target. Spinal Cord 2013; 51: 183–187.
Biglari B, Buchler A, Swing T, Child C, Biehl E, Reitzel T et al. Serum sCD95L concentration in patients with spinal cord injury. J Int Med Res 2015; 43: 250–256.
Eng RH, Seligman SJ . Lumbar puncture-induced meningitis. JAMA 1981; 245: 1456–1459.
Greco I, Day N, Riddoch-Contreras J, Reed J, Soininen H, Kłoszewska I et al. Alzheimer’s disease biomarker discovery using in silico literature mining and clinical validation. J Transl Med 2012; 10: 217.
Acknowledgements
We would like to thank Professor Wagih El Masri for his expert professional opinion in this subject area and the support of the Midland Centre for Spinal Injuries patient fundraisers. This study was supported by the Midlands Centre for Spinal Injuries and the Institute of Orthopaedics, RJAH Orthopaedic Hospital, Oswestry, UK.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Hulme, C., Brown, S., Fuller, H. et al. The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood. Spinal Cord 55, 114–125 (2017). https://doi.org/10.1038/sc.2016.174
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sc.2016.174
This article is cited by
-
Smart closed-loop drug delivery systems
Nature Reviews Bioengineering (2025)
-
Fluid biomarkers for cervical spondylotic myelopathy
Neurosurgical Review (2025)
-
MRI variables and peripheral inflammatory response biomarkers predict severity and prognosis in patients with acute cervical traumatic spinal cord injury
BMC Musculoskeletal Disorders (2024)
-
Acute spinal cord injury serum biomarkers in human and rat: a scoping systematic review
Spinal Cord Series and Cases (2024)
-
A grooved conduit combined with decellularized tissues for peripheral nerve regeneration
Journal of Materials Science: Materials in Medicine (2023)
